Ryu MH - Search Results

1

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.

Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR, Matsumoto S, Lee HJ, Honda H, Kwon OK, Ishikawa T, Lee KH, Nabeshima K, Kong SH, Shimokawa T, Yook JH, Doki Y, Im SA, Hirota S, Hahn S, Nishida T, Kang YK. Kurokawa Y, et al. Among authors: ryu mh. Br J Cancer. 2017 Jun 27;117(1):25-32. doi: 10.1038/bjc.2017.144. Epub 2017 May 23. Br J Cancer. 2017. PMID: 28535156 Free PMC article. Clinical Trial.

2

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.

Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Lee JS, Kang YK. Lee GW, et al. Among authors: ryu mh. J Korean Med Sci. 2003 Dec;18(6):849-54. doi: 10.3346/jkms.2003.18.6.849. J Korean Med Sci. 2003. PMID: 14676442 Free PMC article.

3

Leptomeningeal carcinomatosis in gastric cancer.

Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH. Lee JL, et al. Among authors: ryu mh. J Neurooncol. 2004 Jan;66(1-2):167-74. doi: 10.1023/b:neon.0000013462.43156.f4. J Neurooncol. 2004. PMID: 15015782

4

Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.

Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS. Kim TW, et al. Among authors: ryu mh. Clin Cancer Res. 2004 May 1;10(9):3076-81. doi: 10.1158/1078-0432.ccr-03-0581. Clin Cancer Res. 2004. PMID: 15131046

5

Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.

Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK. Heo YS, et al. Among authors: ryu mh. J Clin Pharmacol. 2004 Oct;44(10):1166-72. doi: 10.1177/0091270004268321. J Clin Pharmacol. 2004. PMID: 15342618

6

Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.

Kim H, Chang HM, Ryu MH, Kim TW, Sohn HJ, Kim SE, Kang HJ, Park S, Lee JS, Kang YK. Kim H, et al. Among authors: ryu mh. J Korean Med Sci. 2005 Jun;20(3):512-5. doi: 10.3346/jkms.2005.20.3.512. J Korean Med Sci. 2005. PMID: 15953881 Free PMC article.

7

Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.

Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK. Ryu MH, et al. Jpn J Clin Oncol. 2006 Jan;36(1):17-24. doi: 10.1093/jjco/hyi212. Epub 2006 Jan 17. Jpn J Clin Oncol. 2006. PMID: 16418188

8

Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.

Lee JL, Kim JY, Ryu MH, Kang HJ, Chang HM, Kim TW, Lee H, Park JH, Kim HC, Kim JS, Kang YK. Lee JL, et al. Among authors: ryu mh. Dig Dis Sci. 2006 Jun;51(6):1043-6. doi: 10.1007/s10620-006-8003-1. Dig Dis Sci. 2006. PMID: 16865565 No abstract available.

9

A case of leukemic pleural infiltration in atypical chronic myeloid leukemia.

Kim HW, Lee SS, Ryu MH, Lee JL, Chang HM, Kim TW, Chi HS, Kim WK, Lee JS, Kang YK. Kim HW, et al. Among authors: ryu mh. J Korean Med Sci. 2006 Oct;21(5):936-9. doi: 10.3346/jkms.2006.21.5.936. J Korean Med Sci. 2006. PMID: 17043433 Free PMC article.

10

Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.

Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK. Lee JL, et al. Among authors: ryu mh. Jpn J Clin Oncol. 2006 Nov;36(11):704-11. doi: 10.1093/jjco/hyl088. Epub 2006 Oct 26. Jpn J Clin Oncol. 2006. PMID: 17068083

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

400 results

Search Page